BackSynAct Pharma AB Overview
SynAct Pharma AB

SynAct Pharma AB Return on Equity

Latest ROE for SynAct Pharma AB: -72.31% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-72.31%

Return on Equity

-72.31%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

SynAct Pharma AB (SYNACT.ST) FAQ

The latest ROE for SYNACT.ST is -72.31%. That is below the Healthcare sector average of 13.1%. Investors often review this figure alongside SynAct Pharma AB's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, SYNACT.ST currently prints -72.31% for ROE, while the sector average sits near 13.1%. That is roughly 651.8% below the sector mean. Large gaps often invite a closer look at SynAct Pharma AB's growth, margins, and balance sheet.

Return on Equity shows how effectively SynAct Pharma AB converts resources into returns. At -72.31%, SYNACT.ST may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SYNACT.ST's ROE (-72.31%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack SynAct Pharma AB's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.